Last reviewed · How we verify
Huangqi-Guizhi-Wuwu granules — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Huangqi-Guizhi-Wuwu granules (Huangqi-Guizhi-Wuwu granules) — Nanjing NingQi Medicine Science and Technology Co., Ltd.. Huangqi-Guizhi-Wuwu granules is a traditional Chinese medicine formulation that enhances immune function and improves microcirculation to support cardiovascular health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Huangqi-Guizhi-Wuwu granules TARGET | Huangqi-Guizhi-Wuwu granules | Nanjing NingQi Medicine Science and Technology Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Huangqi-Guizhi-Wuwu granules CI watch — RSS
- Huangqi-Guizhi-Wuwu granules CI watch — Atom
- Huangqi-Guizhi-Wuwu granules CI watch — JSON
- Huangqi-Guizhi-Wuwu granules alone — RSS
Cite this brief
Drug Landscape (2026). Huangqi-Guizhi-Wuwu granules — Competitive Intelligence Brief. https://druglandscape.com/ci/huangqi-guizhi-wuwu-granules. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab